Patent ID: 6261791
Filing Date: 2001-07-17
Classification: A61K,A61P,C07K,G01N

Abstract:
A method for diagnosing in a subject any of the cancers selected from the group consisting of prostate cancer, bladder carcinoma and bone metastases of prostate cancer which comprises quantitatively determining in a tissue sample from the subject the number of cells expressing the Prostate Stem Cell Antigen (PSCA) protein using an antibody from the group consisting of a monoclonal antibody designated 1G8 (ATCC No. HB-12612), 2A2 (ATCC No. HB-12613), 2H9 (ATCC No. HB-12614), 3C5 (ATCC No. BB-12616), 3E6 (ATCC No. HB12618), 3G3 (ATCC No. HB-12615), or 4A10 (ATCC No. HB-12617) and comparing the number of cells so determined to the number of cells in a sample from a normal subject, the presence of a measurable increase in the number of cells indicating the presence of the cancer.